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a b s t r a c t
Tuberculosis (TB) continues to pose a serious global health threat, and the current vaccine, BCG, has vari-
able efficacy. However, the development of a more effective vaccine is severely hampered by the lack of
an immune correlate of protection. Candidate vaccines are currently evaluated using preclinical animal
models, but experiments are long and costly and it is unclear whether the outcomes are predictive of effi-
cacy in humans. Unlike measurements of single immunological parameters, mycobacterial growth inhi-
bition assays (MGIAs) represent an unbiased functional approach which takes into account a range of
immune mechanisms and their complex interactions. Such a controlled system offers the potential to
evaluate vaccine efficacy and study mediators of protective immunity againstMycobacterium tuberculosis
(M.tb). This review discusses the underlying principles and relative merits and limitations of the different
published MGIAs, their demonstrated abilities to measure mycobacterial growth inhibition and vaccine
efficacy, and what has been learned about the immune mechanisms involved.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
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1. Introduction
The development of vaccines against several pathogens has
been greatly expedited by the identification of a biomarker or
immune correlate of protection [1]. Such biomarkers allow the
http://dx.doi.org/10.1016/j.vaccine.2016.07.058
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down-selection of novel vaccine candidates at an early preclinical
stage of development and provide a relevant measure of immuno-
genicity in phase I trials, guiding progression into efficacy trials.
There is currently no robust or reliable biomarker of protection
for tuberculosis. Although IFN-c is known to be essential for
immunity against TB [2–5], and is widely used as the primary
immunological readout in candidate vaccine studies, there are
many reports of its failure to correlate with protection [6–9]. The
field has focused largely on identifying T cell signatures of efficacy,
such as polyfunctionality which has been shown to be protective in
HIV [10] and Leishmania [11]. In a study of BCG vaccinated infants
in the Western Cape of South Africa, the frequency and more
extended cytokine profile ofM.tb specific T cells was unable to dis-
criminate between protected and non-protected infants [12]. How-
ever, a more recent study in the same population found that the
BCG antigen-specific IFN-c ELISpot response was associated with
reduced risk of TB disease. Furthermore, a correlation was
observed between Ag85A specific IgG and risk of developing TB
disease over the next 3 years of life, suggesting that protective
immunity may not be restricted to the T cell compartment [13].
One alternative to measuring predefined individual parameters
is the use of mycobacterial growth inhibition assays (MGIAs),
which take into account a range of immune mechanisms and their
complex interactions. These systems utilise whole blood or periph-
eral blood mononuclear cells (PBMCs), and measure ability to inhi-
bit growth of mycobacteria following in vitro infection. Using
samples taken pre- and post-vaccination, functional efficacy may
be assessed without the requirement for in vivo Mycobacterium
tuberculosis (M.tb) challenge or natural infection. This provides
potential to reduce the number of animals subjected to M.tb infec-
tion procedures categorised as ‘Moderate’ in severity by the Home
Office. Furthermore, such assays permit evaluation of efficacy
against different M.tb strains and clinical isolates, and the down-
selection of candidates progressing to virulent challenge experi-
ments in larger animal models such as non-human primates
(NHPs). These goals are in line with the ‘Replacement’ criteria of
the National Centre for Replacement, Refinement and Reduction
of Animals in Research (NC3Rs) [14]. With the need for a more
effective vaccine more pertinent than ever, the continued elusive-
ness of a correlate of protection, and an increased emphasis on the
3Rs, there has been a resurgence of interest in MGIAs. These assays
are also applicable to other areas of TB research including drug
evaluation and analysis of clinical patient samples. We review
the methods and findings of the major reported MGIAs and pro-
gress made in understanding the underlying immune mechanisms
(see Fig. 1 and Table 1).
2. Early MGIAs
Early work by Youmans et al. demonstrated that splenocytes
from immune mice produce secretory products, or ‘lymphokine’,
upon stimulation with mycobacteria. In one of the first examples
of an MGIA, addition of this lymphokine to mouse peritoneal
macrophages enhanced inhibition of M.tb growth in vitro [15].
Crowle et al. later adapted this technique for use with PBMC iso-
lated from healthy volunteers considered either immune (Tuber-
culin skin test (TST)-positive or recently vaccinated with BCG) or
non-immune (TST-negative) to BCG [16]. Lymphocytes were cul-
tured for 72 h with antigen (trypsin-extracted soluble antigen/tu-
berculoprotein) to induce lymphokine production. Macrophages
were then infected with mycobacteria and cultured for a further
7 days. Only lymphocytes from immune donors were able to pro-
duce lymphokine upon stimulation, and macrophages incubated
with this lymphokine showed enhanced inhibition of intracellular
bacillary replication. The authors extended their studies to demon-
strate the inhibitory effect of vitamin D3 on mycobacterial growth
in macrophages [17]; a finding later independently confirmed [18].
A similar assay was used to assess inhibition of mycobacterial
growth in murine peritoneal macrophages or human alveolar
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Fig. 1. Classification of MGIAs used in TB vaccine studies and described in this review.
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lavage cells, showing that both cell types could inhibitM.tb growth
[19].
The first application of an MGIA in a vaccine study was reported
by Cheng et al. in 1988 [20]. Rather than addition of lymphokine,
monocyte monolayers received pulsed exposures to autologous
stimulated lymphocytes for 2 h each day over 3 days. Samples
were taken from healthy British school children pre- and 8 weeks
post-BCG vaccination. Monocyte monolayers were infected with
M. microti for 24 h and the change in number of live bacteria in
monolayers and supernatants over 4 days quantified by colony
counts. Mycobacterial growth was significantly inhibited at days
3 and 4 of the culture using cells from post- compared with pre-
BCG vaccination, reflecting the protective effect of BCG vaccination
in this population [21]. The same group later applied this assay to a
study of PPD-negative children receiving BCG vaccination in Chin-
gleput, India [22]. There was no change in mycobacterial growth, in
keeping with epidemiological evidence for a lack of protective effi-
cacy of BCG vaccination in this population [23].
3. PBMC-based MGIAs
In 1998, Silver et al. developed a system using low-level infec-
tion of isolated monocytes with M.tb H37Rv for 1 h, followed by
a 7 day culture either alone or with unstimulated autologous lym-
phocytes [24]. This assay is referred to as the ‘primary lymphocyte
inhibition assay’. Addition of unstimulated lymphocytes resulted
in significant inhibition of mycobacterial growth after 4 and 7 days
of culture for PPD-negative as well as positive subjects, suggesting
this assay may be measuring early innate aspects of immunity. A
role for such mechanisms in vivo is supported by observations that
some individuals remain PPD-negative and disease-free despite
prolonged exposure to active TB patients [25]. In 2002, a study
was conducted comparing three different MGIAs and other poten-
tial markers of protective immunity toM.tb [26]. Ten PPD-negative
individuals from the US were vaccinated with BCG, 8 of whom
received a BCG revaccination 6 months later. The primary lympho-
cyte inhibition assay detected enhanced mycobacterial growth
inhibition at 4 months post-primary BCG vaccination and
2 months post-revaccination compared with baseline, though this
was not statistically significant by ANOVA [26].
A more complex ‘secondary lymphocyte inhibition assay’ was
developed by Worku et al., in which antigen-specific T cells were
expanded by stimulation prior to co-culture with infected mono-
cytes [27]. Adherent monocytes were cultured for 6 days followed
by overnight infection with BCG. In parallel, PBMC were cultured
for 7 days in media alone or with the addition of antigen (mycobac-
terial whole lysate/live BCG or Tetanus toxoid as a control).
Expanded effector T cells were then added to autologous monocyte
targets for 72 h. Interestingly, stimulation with mycobacterial anti-
gens resulted in a considerable expansion of cd TCR-positive T
cells, while no other T cell subsets increased significantly. Inhibi-
tion of BCG growth was enhanced in co-cultures containing T cells
expanded with mycobacterial antigens compared with control
unexpanded lymphocytes, and was increased 2-fold following
BCG vaccination in 3 out of 5 individuals [27]. In the MGIA compar-
Table 1
Overview of MGIAs used in vaccine studies and main findings.
References Compartment Method overview Vaccine effect Immune mechanisms
Cheng et al.
[20,22]
Human
PBMC
Monocytes infected with M. microti
and pulsed with stimulated
lymphocytes for 2 h per day over
3 days
Mycobacterial growth inhibition in pulsed
monolayers at 8 weeks post-BCG compared
with pre-vaccination in UK but not South
Indian children
Observed differences between groups were
not reflected in levels of cytokines such as
GM-CSF
Silver et al.
[24,26]
Human
PBMC
Monocytes infected with M.tb in 96
well plate; autologous lymphocytes
(PBL) added
In US adults, PBL-mediated inhibition
increased non-significantly at 4 months post-
BCG and remained elevated
CD4+ (but not CD8+) T cells contributed to
inhibition in PPD-positive (but not negative)
subjects
Worku et al.
[27,28]
Human
PBMC
Monocytes cultured for 6 days then
overnight infection with BCG;
lymphocytes cultured with antigen
stimulation and added to monocytes
Enhanced ability of expanded T cells to inhibit
growth following BCG in 3 out of 5
volunteers; significant reduction in growth at
2 months post-boost in US adults
Growth inhibition mediated by total BCG-
expanded PBMC and cd T cell enriched
fractions; cell-to-cell contact required
Kampmann
et al.
[29,32]
Human
whole blood
Whole blood infected with BCG lux
for 96 h; cells lysed and mycobacteria
quantified by RLU
In US adults, inhibition at 8 weeks post-BCG
revaccination; in SA infants inhibition at 3–
6 months post primary BCG
Blocking IFN-c, IFN-a and IL-12 resulted in a
partial increase in growth
Wallis et al.
[34,38]
Human
whole blood
Whole blood infected with M.tb for
72 h with 360 mixing; cells lysed
and mycobacteria quantified by
Bactec MGIT TTP
Inhibition in 4 out of 10 US adults following
primary BCG (waned by 6 months but
recurred after boost); 3 subjects responded
after boost
Inhibition of TNF-a or removal of both CD4+
and CD8+ T cells reduced growth inhibition in
tuberculin-positive donors
Fletcher
et al.
[39]
Human
whole blood/
PBMC
Whole blood/PBMC infected with
BCG for 96 h with 360 mixing; cells
lysed and mycobacteria quantified by
Bactec MGIT TTP
Significantly enhanced inhibition at 4 and
8 weeks post primary BCG in UK adults using
PBMC but not whole blood MGIT; no effect of
revaccination
No correlation with PPD-specific IFN-c
ELISpot
Parra et al.
[47,52]
Mouse
splenocytes/
BMM/
Bone marrow macrophages cultured
for 7 days; 2 h infection with M.tb
then addition of splenocytes
Enhanced inhibition in BMM/ cocultured
from BCG vaccinated mice compared with
naïve controls; correlation between inhibition
and in vivo protection of 5 novel vaccines
Immune cocultures consistently showed
upregulation of IFN-c, GDF-15, IL-21, IL-27
and TNF-a
Marsay
et al.
[49]
Mouse
splenocytes
Splenocytes infected with BCG for
96 h with 360 mixing; cells lysed
and mycobacteria quantified by
Bactec MGIT TTP
Inhibition significantly enhanced in
splenocytes from BCG vaccinated mice
compared with control mice
Mycobacterial growth correlated positively
with lysosome pathway genes, and negatively
with proinflammatory genes
Carpenter
et al.
[50]
Cattle
PBMC
PBMC from immunised animals
expanded by PPD stimulation and
added to BCG-infected autologous
macrophages
BCG growth inhibited in cultures containing
autologous PBMC from both immunised and
control animals
Degree of inhibition not correlated with IFN-c
production and not affected by addition of
rIFN-c
Denis et al.
[51]
Cattle
PBMC
PBMC from immunised animals
expanded by PPD stimulation and
added to BCG-infected autologous
macrophages
BCG growth inhibited in cultures containing
autologous PBMC from both immunised and
control animals, though to a greater extent in
immunised animals
Inhibition by PBMC from vaccinated (but not
control) animals partly abrogated by
neutralisation of IFN-c and NO; CD4+ cells
important in controls but both CD4+ and CD8
+ in vaccinated animals
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ison study, secondary lymphocyte inhibitory responses were
increased compared with baseline responses at 6 months after pri-
mary BCG vaccination. Mycobacterial growth inhibition was also
enhanced at 2 and 6 months post-revaccination compared with
baseline [26].
In a further study, growth inhibition was enhanced at 2 and
6 months following BCG vaccination in 10 volunteers [28]. When
T cells were stimulated with purified mycobacterial antigens,
levels of resulting growth inhibition varied depending on the anti-
gen used. Interestingly, there was a 4-fold increase in mycobacte-
rial growth in co-cultures containing unstimulated T cells or T cells
expanded with irrelevant antigens compared with monocytes cul-
tured alone [28]. This is inconsistent with the findings of Silver
et al., who reported reduced growth following the addition of
non-expanded T cells to infected monocyte cultures [24]. The
authors suggest that such differences may be attributed to the
use of fresh cells and the 10-fold greater concentration of mono-
cytes in the Silver assay [28].
4. Whole blood MGIAs
Kampmann et al. developed a whole blood assay using BCG
transfected with luciferase (BCG-lux) as a reporter [29]. Hepari-
nised whole blood diluted 1:2 with media was inoculated with
BCG-lux for 96 h followed by hypotonic cell lysis. Mycobacterial
growth was measured in relative light units (RLU) and expressed
as a ratio of growth in the sample relative to a control. This method
has been described in detail [30], and was later optimised for use
with smaller blood volumes to improve suitability for paediatric
studies [31]. Initial studies showed that in vitro growth of BCG
lux was significantly lower in whole blood, but not plasma, from
tuberculin-positive individuals compared with tuberculin-
negative individuals [29]. In the MGIA comparison study in adults
from the US, the luciferase assay detected a significant vaccine-
induced reduction in BCG lux growth at 8 months (2 months after
revaccination), but not following primary vaccination [26]. In a fur-
ther study of BCG vaccination in the TB endemic setting of South
Africa, 33 out of 50 infants showed a reduction in in vitro BCG
lux growth at 3–6 months post-vaccination compared with base-
line [32]. Finally, this assay demonstrated reduced ability of whole
blood from HIV-infected infants to inhibit mycobacterial growth
compared with healthy control infants [33].
In 2001, Wallis et al. described a whole blood MGIA to measure
the bactericidal activity of anti-TB drugs [34]. Blood was collected
before, and at intervals following, drug administration and inocu-
lated with 104 CFU of M.tb. Following a 72 h culture, host cells
were lysed and mycobacteria sedimented, resuspended and inocu-
lated into BACTEC Mycobacteria Growth Indicator Tubes (MGIT).
The difference between the time to detection (TTD) of the control
and experimental cultures was used to determine the extent of
mycobacterial growth inhibition. This quantification system has
several advantages over traditional methods, including the use of
a validated and highly sensitive clinical diagnostics platform. Inhi-
bition was shown to correlate with sterilising activity observed
in vivo during therapy. In a study of HIV-negative volunteers
receiving the standard 6 month treatment for drug-sensitive pul-
monary TB, the cumulative bactericidal activity observed during
treatment correlated with the rate of decrease of sputum bacillary
load (defined by CFU) during the first 4 weeks and was associated
with time to conversion to sputum negativity [35]. The authors
subsequently extended their studies to compare the capacities of
different mycobacterial strains for survival and growth [36,37].
Cheon et al. applied the MGIT assay to a study of repeated BCG
vaccination in 8 tuberculin-negative volunteers from the US [38].
Subjects received primary BCG vaccination at day 0 and a
homologous boost 6 months later. Four subjects showed enhanced
mycobacterial growth inhibition following the first vaccination,
and their responses waned at 6 months but recurred after revacci-
nation. Three subjects responded only after the second vaccination
and the remaining three subjects showed no response. The authors
suggest that such heterogeneity among subjects may be influenced
by host genetic factors [38].
In 2013, the Wallis whole blood MGIA was employed by
Fletcher et al. alongside a PBMC-based adaptation [39]. 30 British
adults received either a primary BCG vaccination or homologous
boost to historical BCG. Following primary BCG vaccination, PBMC
mediated significantly enhanced growth inhibition at both 4 and
8 weeks following vaccination. The assay showed no effect of
revaccination using either compartment [39]. Though consistent
with reports indicating that primary, but not secondary, BCG vac-
cination can improve protection against TB disease [40–43], these
findings are in contrast to those of Hoft et al. and Cheon et al.
[26,38]. Possible explanations for such differences include the
use of a UK population in which primary BCG vaccination is known
to have high efficacy [44], and a longer interval between primary
vaccination and revaccination with BCG [39]. The whole blood
MGIT assay was also applied in a BCG challenge study comparing
anti-mycobacterial immunity induced by vaccination with BCG
or MVA85A, but did not detect any differences between groups
[45].
The PBMC MGIT assay was recently performed as part of a case-
control analysis of immune correlates of risk of TB disease in BCG
vaccinated infants from South Africa. An association was observed
between reduced risk of TB disease and both BCG-specific IFN-c
ELISpot responses and Ag85A antibodies, but not mycobacterial
growth inhibition [13]. The lack of correlation with the MGIT assay
may have been due to the low frequency of BCG antigen specific T-
cells (mean of 55, range 0 to 337 SFC per million in frozen PBMC).
As only 1  106 PBMC were used in the MGIA due to limited cell
availability, few effector cells would have been present in the cul-
ture. Furthermore, autologous serum was not used and therefore
any potential protective effect of antibodies was not measured
[13].
5. MGIAs in preclinical animal models
In addition to human samples, MGIAs have been described
using cells from mice [46–49] and cattle [50,51]. Developing
MGIAs for use with animal samples provides an opportunity to test
experimental vaccine candidates and importantly to correlate
results with in vivo protection from M.tb challenge, thus providing
biological validation.
In a murine ex vivo culture system developed by Cowley and
Elkins, bone marrow macrophages (BMM/) were cultured for
7 days and then infected with M.tb Erdman for 2 h [46]. Spleno-
cytes were primed by in vivo infection with M.tb followed by
chemotherapy to clear infection. Addition of harvested primed
splenocytes to the macrophage cultures resulted in a significant
reduction in M.tb growth. A similar method described by Parra
et al. demonstrated enhanced inhibition of M.tb growth in BMM/
co-cultured with splenocytes from BCG vaccinated mice compared
with naïve controls [47]. M.tb growth was measured using spleno-
cytes from mice immunised with 5 different vaccines, all of which
showed enhanced inhibition at day 7 compared with naïve con-
trols. Furthermore, there was a significant correlation between
in vitro mycobacterial growth inhibition and in vivo protective
immunity at 28 days post pulmonary M.tb challenge [47]. Kolibab
et al. replicated these findings using an isoniazid-resistant BCG
strain in place of virulentM.tb, and showed a significant correlation
between inhibition of the two strains [52].
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In 2008, Sada-Ovalle et al. employed a macrophage co-culture
system whereby purified peritoneal macrophages were cultured
with opsonised H37Rv M.tb for 2 h, followed by addition of naïve
splenocytes for 3 days. There was a >50% reduction in CFU in co-
cultures containing splenocytes compared with cultures of
infected macrophages alone [48]. Work by Marsay et al. in 2013
used a murine splenocyte MGIA adapting the methods of Wallis
et al. employing the BACTEC MGIT system. Splenocytes from BCG
immunised mice were better able to inhibit growth of BCG in cul-
ture compared with those from naïve animals. This corresponded
with protection from in vivo challenge with M.tb, where the same
experimental conditions conferred protection in the immunised
but not naïve group [49]. Details of the optimised direct splenocyte
MGIT assay are available on BioRxiv [53].
Both Parra et al. and Marsay et al. correlated differences in
mycobacterial growth inhibition between groups with protection
in experimentally-matched mice [47,49], thus demonstrating the
utility of animal MGIAs for biological validation. One limitation
of the murine model is that mice must be sacrificed to obtain
splenocytes, and thus the same animals cannot be tested in an
MGIA and in vivo challenge. Non-human primates (NHP) and cattle
provide an opportunity to correlate in vitro and in vivo outcomes on
a per-animal basis, though to our knowledge there have been no
published NHP MGIAs. Preliminary work applying the whole blood
MGIT assay to a study of Cynomolgus macaques has demonstrated
a correlation between mycobacterial growth inhibition following
primary vaccination and protection from BCG challenge as mea-
sured by lymph node CFU (Harris S et al. submitted).
In 1997, the methods of Rook et al. were adapted for use in a
study of BCG vaccination in cattle. In this bovine MGIA, the addi-
tion of autologous lymphocytes to infected macrophages mediated
inhibition of BCG growth. However, there was no significant differ-
ence between cells taken from BCG vaccinated compared with
naïve animals, suggesting that cattle may already possess a high
level of innate resistance [50]. Conversely, a later study suggested
that BCG vaccination did in fact mediate improved inhibition [51].
To date there have been no studies correlating in vitro and in vivo
outcomes in cattle.
In summary, there is evidence from multiple animal models
that mycobacterial growth inhibition can be observed in vitro fol-
lowing BCG immunisation in animals, and that this can be corre-
lated with protection from challenge with M.tb. While an MGIA
is unlikely to replace M.tb challenge for the assessment of TB vac-
cine candidates in small animal models, it may help in the prior
refinement of vaccine dose or regimen, and provide an alternative
to pathogenic challenge in larger animals such as NHPs. Further-
more, this would offer some support for the hypothesis that an
MGIA could represent a useful substitute for ethically unacceptable
challenge in human clinical trials.
6. Immune mechanisms involved in mycobacterial growth
inhibition
MGIAs provide a valuable tool for elucidating the mechanisms
underlying immune control of mycobacterial growth, which may
be of relevance to protection against M.tb in vivo. Such systems
are controlled and easily manipulated, for example through the
depletion or addition of specific cell types or immune mediators.
Many of the studies described have investigated the role of T cells
and key cytokines.
6.1. Roles of specific T cell subsets
Th1 cell mediated immunity is known to be important in pro-
tection against TB [46–57]. In the primary lymphocyte inhibition
assay, depletion of CD4+ T cells reduced the growth inhibiting
capacity of unstimulated lymphocytes from PPD-positive subjects
but not PPD-negative subjects when added to infected monocytes.
Depletion of CD8+ T cells did not impact the inhibiting capacity of
lymphocytes from either group [24]. Worku and Hoft enriched
both CD4+ and CD8+ T cells from total PBMC expanded with live
BCG and co-cultured with infected monocytes in the secondary
lymphocyte inhibition assay. Although mycobacterial growth inhi-
bition was enhanced with enriched CD4+ or CD8+ T cells compared
with unstimulated total PBMC, this did not reach statistical signif-
icance. BCG-stimulated total PBMC and cd T cell enriched fractions
did however mediate superior levels of control [28]. In the Cheon
whole blood MGIT study, depletion of CD4+ and CD8+ T cells con-
currently reduced ability to inhibit M.tb growth. However, CD4+ T
cells alone did not have a significant effect, and depletion of CD8+ T
cells alone had an effect in PPD-positive subjects only, at 48 h but
not 96 h of culture. Interestingly, the growth of anM.tb clinical iso-
late was unaffected by the depletion of either, or both, T cell sub-
sets [38].
Cowley and Elkins found that addition of whole splenocytes in
the murine co-culture reduced M.tb growth by 95%, whereas CD4
+ T cells reduced growth by 89% and CD8+ T cells by 82% compared
with cultures containing infected macrophages alone [46]. In the
bovine MGIA, the ability of lymphocytes from naïve animals to
control mycobacterial growth was abrogated by CD4+, but not
CD8+, T cell depletion. However, both CD4+ and CD8+ T cell deple-
tion was associated with increased mycobacterial growth in co-
cultures of cells from BCG vaccinated cattle [51].
Despite representing a minor population of total human blood
lymphocytes, it has been postulated that cd T cells may play a role
in protective immunity against M.tb [54]. Hoft et al. demonstrated
that BCG vaccination enhanced responsiveness of cd T cells to
mycobacteria, suggesting a memory-like phenotype [55]. They
later found that the stimulation stage of the secondary lymphocyte
inhibition assay predominantly expanded cd T cells and that addi-
tion of these cells to infected monocytes significantly improved
mycobacterial growth inhibition [27,28]. The authors have recently
extended this work to show that c9d2 T cells (a major cd subset
that can serve as professional APCs) produce soluble granzyme A
in a TNF-a dependent manner, which correlates with their ability
to inhibit mycobacterial growth. Indeed, purified granzyme A alone
mediated inhibition when added directly to infected humanmono-
cytes [56].
Though CD4+ and CD8+ T cells appear to have little or no influ-
ence in some reports, it is possible that the individual effect medi-
ated by each cell type is not strong enough to observe, or that one
cell type can compensate for the loss of another. i.e. redundancy
Furthermore, many of these studies inoculate with surrogate avir-
ulent mycobacteria such as BCG, which lack immunogenic proteins
including ESAT-6 and HspX, and as such may fail to activate an
effective specific response [57]. Where historically vaccinated indi-
viduals were used, it is possible that they do not mount an effective
long-term cellular response; indeed a proposed explanation for the
poor efficacy of the BCG vaccine is a failure to induce central mem-
ory T cells [58–60]. Finally, mice may not be the most appropriate
model for investigating the role of CD8+ T cells as they lack some
features relating to CD8+ T cell function and specificity such as
the cytotoxic protein granulysin [61].
6.2. Cytokines
There is a plethora of evidence supporting a central role for IFN-
c in the immune response to TB disease [2–5,62,63]. However, in
both TB patients and healthy vaccinated humans and animals, hav-
ing more IFN-c secreting T cells, or greater levels of IFN-c, is asso-
ciated with bacterial burden post-challenge and progression to
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active disease rather than protection [6–9,64,65]. Consistent with
these observations, many of the MGIA studies described reported
no correlation between IFN-c and mycobacterial growth inhibition
[26,32,39]. In all cases, IFN-c responses were significantly
enhanced following BCG vaccination but did not appear to be driv-
ing the improved control of mycobacteria observed.
In the primary lymphocyte assay, Silver et al. found that addi-
tion of recombinant IFN-c and TNF-a to infected monocytes had
little or no effect on mycobacterial growth, and addition of block-
ing antibodies to IFN-c, TNF-a and IL-12 to co-cultures of unstim-
ulated lymphocytes and infected monocytes failed to significantly
alter mycobacterial growth [24]. Addition of monoclonal antibod-
ies against the same cytokines resulted in partial enhancement of
mycobacterial growth in the whole blood lux assay [29]. Blocking
all cytokine production only partially reduced the ability of lym-
phocytes to enhance growth inhibition, suggesting a role for direct
contact-mediated activation of monocyte function by lymphocytes
[24]. Using the secondary lymphocyte inhibition assay, cell contact
was confirmed as a requirement for inhibitory activity, as the high
levels of secreted IFN-c alone were not responsible for the
mycobacterial growth inhibition observed. Increases in TNF-a, IL-
6, TGF-b and VEGF mRNA expression were associated with
enhanced mycobacterial growth [28]. In the Cheng studies, there
was no evidence for the contribution of cytokines such as MAF
and GM-CSF to the differences in MGIA results observed between
pre- and post-BCG vaccination or between British and Indian chil-
dren [22].
IFN-c appears to be more influential in murine MGIA models,
with several reports demonstrating that rIFN-c increases inhibition
of M.tb by murine but not human cells [19,65,66]. Cowley and Elk-
ins showed that addition of neutralising antibodies to IFN-c and
TNF-a had a deleterious effect on the ability of immune murine
splenocytes to control M.tb growth. Conversely, growth of M.tb
was still reduced when IFN-cR knock-out BMM/ were co-
cultured with immune splenocytes compared with naïve or no
splenocytes [46]. In the Marsay et al. direct splenocyte MGIT assay,
IFN-c was one of 9 out of 115 genes whose expression correlated
significantly with mycobacterial growth inhibition [49]. Parra
et al. found that IFN-c (together with TNF-a, GDF15, IL-21 and
IL-27) was consistently upregulated in immune co-cultures from
immunised mice [47]. These findings are consistent with reports
of the importance of IFN-c in mice in terms of its ability to induce
nitric oxide synthase (NOS2) [67,68]. Finally, addition of rIFN-c to
macrophages pre- or post-infection did not alter mycobacterial
growth in the Carpenter bovine assay, but the ability of cells from
BCG vaccinated cattle to inhibit mycobacterial growth was par-
tially abrogated by neutralising antibody to IFN-c [50].
In summary, while IFN-c is clearly influential in murine assays,
this cytokine appears to exert a relatively modest effect in human
MGIAs and is at best only partially responsible for mediating inhi-
bition of mycobacterial growth. It may be that IFN-c and other
cytokines studied have a summative effect, or that different
immune mediators can compensate for their loss in neutralisation
studies. These assays may provide more information about com-
plex host-pathogen interactions and could potentially represent a
more accurate surrogate of protective immunity than measures
of single cytokines such as ELISpots.
6.3. Humoral immunity
Due to the primarily intracellular nature of M.tb, the role of B
cells and antibodies in M.tb infection has been less studied than
cellular immunity, but there is now accumulating evidence sug-
gesting their importance [69]. Although some reports in the litera-
ture indicate induction of specific antibodies following BCG
vaccination [70–73], others do not [74,75]. To our knowledge only
one MGIA study has investigated the contribution of antibodies fol-
lowing vaccination. In a variation of the secondary lymphocyte
inhibition assay, de Valliere et al. pre-incubated BCG with paired
samples of serum from pre- and post-BCG vaccination, followed
by co-culture with purified neutrophils or monocytes. Inhibition
mediated by both cell types was significantly improved by opsinis-
ing BCG in post-vaccination serum; an effect that was reversed by
preabsorption of IgG with Protein G [76]. In a more recent study of
IgG antibodies to arabinomannan (AM), responses correlated with
mycobacterial growth inhibition in the PBMCMGIT at 4 weeks post
BCG vaccination. Using an assay of THP-1 cells coincubated with
paired sera, significantly lower BCG growth rates were seen in cells
treated with post-vaccination sera compared with pre-vaccination
sera [77]. These studies support consideration of the role of M.tb-
specific antibodies in enhancing innate and cell-mediated immune
responses to mycobacteria in vitro.
6.4. Innate immune mechanisms
a. Antigen-presenting cells. Monocytes/macrophages and den-
dritic cells (DCs) effectively phagocytose live mycobacteria
and present antigen on their surface, eliciting a cellular
response. Monocytes in particular provide a reservoir for
mycobacterial survival and replication, and their importance
in MGIAs is highlighted by the associations reported
between the monocyte:lymphocyte (ML) ratio and
mycobacterial growth [50,51,78]. Interestingly, a recent
study showed that qualitative differences in monocyte func-
tion partially explained the ML ratio association with
mycobacterial growth in the PBMC MGIT assay [78]. There
are few reports of MGIAs using dendritic cells, though Denis
et al. extended their bovine studies to demonstrate that
bovine DCs phagocytose and support the replication of M.
bovis intracellularly [79]; consistent with reports using
mouse and human DCs [80–83].
b. Neutrophils. The role of neutrophils in TB is controversial
and not yet fully defined, although several reports indicate
that early recruitment of neutrophils to the site of infection
improves outcome, and risk of infection in TB contacts is
inversely proportional to the peripheral blood neutrophil
count [84]. Martineau et al. demonstrated increased growth
of both BCG-lux and M.tb-lux in neutrophil-depleted com-
pared with undepleted blood from healthy donors using
the previously describe lux MGIA [84]. A similar trend has
been observed using the whole blood MGIT assay (Tanner
R, O’Shea M and Satti I, unpublished data). Other in vitro
studies provide evidence both for and against the ability of
neutrophils to kill internalised mycobacteria, and it may be
that both outcomes are possible in vivo [85].
c. Natural Killer cells. Natural killer (NK) cells are also recruited
to the lung followingM.tb infection in mice, although reports
suggest that their depletion does not affect lung bacterial
load [86]. Human NK cells have been shown to directly lyse
M.tb-infected macrophages in vitro and may also play an
indirect role in restricting mycobacterial growth via promo-
tion of CD8+ and cd T cell responses [87–90]. Brill et al.
applied the primary lymphocyte inhibition assay to demon-
strate that NK cells isolated from both PPD-positive and
PPD-negative subjects could enhance inhibition of intracel-
lular M.tb growth in an apoptosis-dependent manner [91].
7. Comparison of different MGIAs
It is clear from the MGIA comparison study of Hoft et al. that
different MGIAs do not consistently correlate in outcome and are
likely measuring different aspects of immunity [26]. Addition of
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unstimulated lymphocytes to infected macrophages, as in the pri-
mary lymphocyte inhibition assay [24], or use of whole PBMC as in
the MGIT assay [39], provides an unbiased representation of the
peripheral response. However, it is possible that innate non-
specific mechanisms are overemphasised in such a model, evi-
denced by the lack of a longer-term effect of BCG vaccination
[39] and the inhibitory capacity of cells from PPD-negative volun-
teers [24,50]; though the latter may be due to mycobacterial reac-
tive MR1- or CD1-restricted T cells present in these individuals
[92,93]. One potential solution for increasing sensitivity to mea-
sure a memory response is expansion of antigen-specific T cells
by stimulation, as in the secondary lymphocyte inhibition assay
[27], although cd T cells may be disproportionately represented.
Whole blood assays [32,34] take a less biased approach, accounting
for the effects of neutrophils and erythrocytes, as well as antibod-
ies and complement in the serum.
Different MGIAs may be suited to different purposes. When
attempting to measure a vaccine-induced adaptive immune
response, one may argue that innate mechanisms such as neu-
trophils in whole blood are less relevant, and a strong effect could
in fact ‘mask’ the functionality of a long-term specific response.
Furthermore, whole blood assays cannot distinguish between
intracellular and extracellular mycobacterial growth, while a cellu-
lar assay permits removal of non-phagocytosed bacteria by wash-
ing. It is likely difficult to delineate small vaccine effects in the
more complex whole blood model, where factors such as haemo-
globin may be confounding (Tanner R et al. submitted). As such,
whole blood may be less appropriate than cellular assays for vac-
cine efficacy testing, though well-suited to other purposes such
as drug evaluation and comparison of different disease states in
clinical samples. A simpler unbiased assay such as the MGIT,
requiring no antigen stimulation or specific immune reagents,
could allow direct comparison of a wide range of candidate vacci-
nes across different species.
There are also logistical advantages to certain types of MGIA.
The whole blood assays described require small volumes of blood,
making them a superior choice where sample availability is limit-
ing; for example in paediatric studies. However, the whole blood
lux assay [32] is limited to recombinant mycobacterial strains
expressing the lux gene; the other assays are not constrained in
this way and may be utilised to test diverse clinical isolates as
demonstrated by Wallis et al. [36,37]. Use of whole blood requires
that samples are processed on day of acquisition which may be
logistically complex, particularly in resource-limited trial settings.
Using cryopreserved PBMC could aid in transferability of the assay
to different sites and retrospective study of samples from historical
trials. Ability to thaw cells at a later time also eliminates day-to-
day variability. A PBMC assay may be more transferable between
species where blood volume is limited, allowing biological valida-
tion with in vivo challenge and bridging to human samples with
the same assay.
As described, MGIAs in preclinical animal models provide the
opportunity to test and down-select novel vaccine candidates.
However, in small animals, permissible blood volumes may pre-
clude the use of whole blood MGIAs, and splenocytes are consid-
ered the most feasible compartment. One limitation of using
murine splenocytes in studies of live replicating vaccines such as
BCG is the propensity for BCG to persist in the spleen [59,94], thus
influencing the immune response in a way that may not be repre-
sentative of the periphery or lung. However, the direct splenocyte
MGIT assay does represent a simpler model than others described
with no requirement for macrophage harvest and culture [49,53].
This may reduce assay variability and improve transferability.
One criticism of many MGIAs is that the cellular compartments
used are not representative of the early immune response in vivo,
where mycobacteria would likely encounter epithelial cells,
dendritic cells and alveolar macrophages in the lung. While previ-
ous assays have made use of alveolar macrophages [19], to our
knowledge no MGIAs have been described infecting dendritic or
epithelial cells. However, other in vitro models have been reported
using an infected alveolar epithelial cell line [95], and dendritic
cells infected with BCG, M.tb H37Rv and the whole mycobacterial
candidate vaccine SO2 to compare immunogenicity [96]. Further
technical improvements in MGIAs may be dependent on advances
in the available technologies for quantitatively measuring interac-
tions between immune cells and bacteria. There are currently few
systems that are widely available, can perform robustly between
laboratories and can be used with CL3 pathogens, constraining fur-
ther development.
8. Conclusions
Functional growth inhibition assays have had some degree of
success in such diverse disease models as malaria [97], HIV [98]
and meningitis [99]. Given the slow-growing, fastidious nature of
mycobacteria, the complexity of challenge models, and the gaps
in our current understanding of TB immunology, developing a suc-
cessful MGIA is an ambitious task. However, as an immune biomar-
ker of protection from TB remains elusive, such an assay could be
game-changing in the field. The utility of an MGIA is two-fold:
evaluating vaccine efficacy and allowing direct study of the medi-
ators of protective immunity against M.tb in a controlled system.
An important starting point in developing such assays is the
proof-of-concept demonstration of a BCG-mediated vaccine effect
in populations where this vaccine is known to be protective. This
has been achieved by a number of groups using both whole blood
and PBMC from different populations including UK children and
UK adults [20,39]. Also key is the demonstration of biological valid-
ity by correlating MGIAs with measures of in vivo protection.
Encouragingly, findings using human assays have generally been
consistent with field efficacy studies, including BCG-induced
improved control of mycobacterial growth in samples from UK
children compared with Indian children [22], UK adults receiving
primary vaccination compared with revaccination [39], and
healthy compared with HIV-infected infants [33]. A correlation
between in vitro outcomes and protection from in vivo challenge
has been demonstrated in some preclinical studies using
experimentally-matched groups of mice [47,49,52] and BCG vacci-
nated macaques (Harris et al. submitted). MGIAs may be applied in
the testing of novel vaccine candidates, where in vitro growth inhi-
bition can be compared with in vivo growth inhibition after viru-
lent M.tb challenge or natural infection. To our knowledge only
two such studies have been published. Parra et al. showed a signif-
icant correlation between MGIA and in vivo protective immunity in
mice following vaccination with 5 different candidates [47]. In a
more recent study, Fletcher et al. showed no difference in PBMC
MGIT outcome between BCG-vaccinated South African infants vac-
cinated with MVA85A and those receiving a Candin placebo, in
keeping with the findings of a Phase IIb efficacy trial. However,
in this study the MGIT assay was unable to discriminate between
infants who went on to develop TB disease during the 3 year
follow-up period and those who did not [13].
The utility of MGIAs in studying the effector functions required
for control of M.tb has also been demonstrated, though results are
variable – likely due to different assays measuring different com-
partments and aspects of immunity. The extent to which CD4+
and CD8+ T cells play a role remains unclear, and while IFN-c
was shown to be important in murine assays, most human MGIA
studies reported no correlation between IFN-c and mycobacterial
growth inhibition. Relationships between immune parameters
may be more complex, illustrated by the associations between
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growth and ML ratio or monocyte functionality. We may also need
to look beyond the classic dogma of Th1 cell mediated immunity –
indeed the importance of both M.tb-specific antibodies and cd T
cells in the secondary lymphocyte inhibition assay has been
reported. MGIAs importantly provide a controlled and relatively
tractable system in which effector functions may be studied
through such techniques as cell depletions and antibody neutrali-
sation. A cell type or other immune mediator found to be impor-
tant in determining mycobacterial growth inhibition in a
validated in vitro assay may identify potential correlates of
immune control of M.tb growth in vivo, which to date remain elu-
sive. There is a need for further and more comprehensive analysis
in this area if we are to more accurately determine the immune
parameters important for growth inhibition.
Although a number of assays have been described and their
potential utility in measuring vaccine efficacy and elucidating
immune mechanisms demonstrated, none have been widely
adopted in vaccine development. This may be in part due to diffi-
culties with reproducibility intrinsic to such functional assays. Fur-
ther work to validate a transferable assay for wider use across
different groups is warranted.
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